Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.

This is amino acids 86 to 100 fragment of class II-associated invariant chain peptide called CLIP. The major histocompatibility complex class II molecule displays peptide fragments of foreign proteins to trigger a defensive reaction from the immune system. Before insertion of the foreign peptides into the binding groove, a place-holding peptide CLIP is removed. This is accomplished by the molecule DM, which is shown to increase the dissociation rate of a CLIP peptide from class II.

Clocapramine hydrochloride hydrate is an antagonist of the 5-HT2A and D2 receptors.